News
Pasithea Therapeutics Announces PAS-004 Abstract Accepted For Poster Presentation At 2024 ASCO Annual Meeting
29 Apr 24
Biotech, News, General
Pasithea Therapeutics Announces The First Cohort Has Completed The Initial Dosing In Its Phase 1 Trial Evaluating PAS-004 In RAS, NF1 And RAF Mutated Cancers
24 Apr 24
Biotech, News, General
Pasithea Therapeutics Announces Opening Of Enrollment In The U.S. For Its Phase 1 Trial Of PAS-004
13 Feb 24
Biotech, News, General
Press releases
Pasithea Therapeutics Announces the First Cohort has Completed the Initial Dosing in its Phase 1 Trial Evaluating PAS-004 in RAS, NF1 and RAF Mutated Cancers
24 Apr 24
Press Releases
Pasithea Therapeutics Announces Opening of Enrollment in the U.S. for its Phase 1 Trial of PAS-004
13 Feb 24
Press Releases